Literature DB >> 3401100

Medical care costs of patients with acquired immunodeficiency syndrome in Richmond, Va. A quantitative analysis.

L G Kaplowitz1, I J Turshen, P S Myers, L A Staloch, A J Berry, J T Settle.   

Abstract

This study examines inpatient charges for 52 adult patients with the acquired immunodeficiency syndrome (AIDS) who had 102 admissions to the Medical College of Virginia Hospitals, Richmond, from October 1983 through December 1986. Complete charge data were available for 81 hospitalizations; the mean charge per hospitalization was +13,830 (SD, +13,610), the average length of stay was 14.8 days (SD, 13.1 days), and the mean per diem charge was +1058 (SD, +802). For patients who received all their AIDS-related medical care at the Medical College of Virginia Hospitals, total lifetime hospital charges averaged +27,264, the mean number of hospital stays was 2.29, and the average length of stay was 12 days. The average length of hospital stay, total charges per hospitalization, and average charge per day of hospitalization decreased over the study period. These findings suggest that inpatient costs of treating individual patients with AIDS are less than initially estimated and are decreasing due to the ability to more effectively manage these patients.

Entities:  

Mesh:

Year:  1988        PMID: 3401100

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  3 in total

Review 1.  The cost of HIV treatment and care. A global review.

Authors:  E J Beck; A H Miners; K Tolley
Journal:  Pharmacoeconomics       Date:  2001-01       Impact factor: 4.981

2.  Effect of changing patterns of care and duration of survival on the cost of treating the acquired immunodeficiency syndrome (AIDS).

Authors:  G R Seage; S Landers; G A Lamb; A M Epstein
Journal:  Am J Public Health       Date:  1990-07       Impact factor: 9.308

3.  The impact of HIV-related illness on employment.

Authors:  E H Yelin; R M Greenblatt; H Hollander; J R McMaster
Journal:  Am J Public Health       Date:  1991-01       Impact factor: 9.308

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.